OncoMatch/Clinical Trials/NCT03216525
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Is NCT03216525 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Alvimopan for bladder cancer.
Treatment: Alvimopan — To determine if Alvimopan during open or robotic radical cystectomy with urinary diversion results in quicker return of bowel function (GI-2 recovery = time to upper \[first toleration of solid food\] and lower \[first bowel movement\] gastrointestinal recovery) compared to placebo.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Performance status
ASA 1–4
Prior therapy
Cannot have received: chemotherapy
Exception: prior neoadjuvant chemotherapy allowed if >1 month before surgery
Chemotherapy for bladder cancer within 1 month of scheduled surgery; prior neoadjuvant chemotherapy allowed
Lab requirements
Kidney function
no end-stage renal disease
Liver function
no severe hepatic impairment
Cardiac function
no heart failure
Patients with severe hepatic impairment [excluded]. Patients with end-stage renal disease [excluded]. Patients with heart failure [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Brigham and Women's Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify